Stock listing

NYSE American:ATNM Actinium Pharmaceuticals, Inc. (Delaware) Stock

Home listing (NYSE American) of Actinium Pharmaceuticals, Inc. (Delaware)

Follow Actinium Pharmaceuticals, Inc. (Delaware) into a list and get an email when it puts out news.

Share price · AMEX:ATNM

$1.05 USD -0.02 (-1.9%)

Close on Nov 20, 2026

Past year -18.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.00 – $1.10 USDNov 20, 2026
Volume
280,659 sharesNov 20, 2026
Market cap
$33.01M USDAt the close on Nov 20, 2026 · price × 31.44M shares outstanding
52-week range
$0.735 – $1.72 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$251,047 USDMedian day 115,250 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Actinium Pharmaceuticals, Inc. (Delaware) logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:ATNM · Home$1.05 USD-0.02 (-1.9%)280,659$1.07$1.10$1.00$1.07Close on Nov 20, 2026
Frankfurt:7AY1€0.948 EUR-0.017 (-1.8%)—€0.948€0.948€0.948€0.965Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:ATNM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.05-0.02-1.9%$1.07$1.10$1.00280,659
$1.07-0.01-0.9%$1.08$1.18$1.03166,488
$1.08-0.27-20.0%$1.33$1.34$1.08326,840
$1.35-0.14-9.4%$1.45$1.49$1.28555,005
$1.49-0.15-9.1%$1.64$1.685$1.465347,947
$1.64+0.05+3.1%$1.60$1.64$1.55180,600
$1.590.000.0%$1.61$1.67$1.53348,100
$1.59+0.02+1.3%$1.52$1.65$1.49115,500
$1.57+0.03+1.9%$1.55$1.61$1.50176,400
$1.54+0.11+7.7%$1.44$1.62$1.43467,400
$1.43+0.13+10.0%$1.28$1.43$1.2889,200
$1.30-0.11-7.8%$1.38$1.39$1.30213,000
$1.41+0.01+0.7%$1.42$1.45$1.36104,300
$1.40-0.03-2.1%$1.40$1.46$1.4075,800
$1.43-0.05-3.4%$1.48$1.53$1.41104,600
$1.48-0.05-3.3%$1.51$1.535$1.45157,700
$1.53+0.15+10.9%$1.38$1.56$1.38181,700
$1.38-0.04-2.8%$1.40$1.42$1.3556,600
$1.42+0.02+1.4%$1.40$1.55$1.40107,000
$1.40-0.12-7.9%$1.50$1.53$1.36205,800
$1.52-0.08-5.0%$1.60$1.63$1.469242,000
$1.60+0.22+15.9%$1.33$1.66$1.33827,800
$1.38-0.02-1.4%$1.38$1.409$1.33357,900
$1.40+0.08+6.1%$1.36$1.50$1.35900,300
$1.32+0.19+16.8%$1.14$1.40$1.13657,200
$1.13+0.07+6.6%$1.09$1.15$1.05174,400
$1.06+0.085+8.7%$0.95$1.07$0.95143,200
$0.975-0.025-2.5%$0.99$1.023$0.95284,600
$1.00-0.06-5.7%$1.07$1.07$0.99687,900
$1.06-0.04-3.6%$1.09$1.09$1.02997,600
$1.10+0.02+1.9%$1.09$1.12$1.07105,800
$1.08+0.01+0.9%$1.09$1.10$1.06104,900
$1.07-0.04-3.6%$1.08$1.12$1.05100,100
$1.11-0.09-7.5%$1.20$1.22$1.02439,600
$1.20+0.03+2.6%$1.16$1.24$1.16115,000
$1.17+0.02+1.7%$1.15$1.19$1.1281,800
$1.15+0.03+2.7%$1.11$1.15$1.1190,800
$1.12-0.02-1.8%$1.14$1.20$1.1095,100
$1.14-0.04-3.4%$1.17$1.17$1.1462,022
$1.18-0.02-1.7%$1.18$1.20$1.1775,373
$1.20+0.01+0.8%$1.19$1.205$1.1828,400
$1.19+0.01+0.8%$1.19$1.25$1.1884,800
$1.18+0.01+0.9%$1.17$1.21$1.16130,400
$1.17-0.03-2.5%$1.18$1.22$1.1754,500
$1.20-0.02-1.6%$1.24$1.24$1.16699,400
$1.22+0.03+2.5%$1.18$1.23$1.18146,200
$1.19-0.05-4.0%$1.26$1.26$1.1856,700
$1.24-0.01-0.8%$1.26$1.275$1.2459,800
$1.25-0.03-2.3%$1.28$1.32$1.2596,100
$1.28-0.12-8.6%$1.41$1.418$1.25301,500
$1.40+0.09+6.9%$1.31$1.42$1.285238,200
$1.31+0.08+6.5%$1.25$1.34$1.23226,800
$1.230.000.0%$1.24$1.305$1.22366,600
$1.23+0.20+19.4%$1.06$1.25$1.06574,100
$1.03-0.02-1.9%$1.05$1.055$1.0254,000
$1.05+0.05+5.0%$1.02$1.06$1.0172,000
$1.00+0.004+0.4%$1.00$1.04$1.0074,900
$0.996-0.024-2.4%$1.01$1.022$0.99630,100
$1.02+0.01+1.0%$1.03$1.03$1.0134,800
$1.01+0.01+1.0%$1.00$1.028$0.97111,600
$1.00-0.01-1.0%$1.01$1.05$1.0092,900
$1.01-0.07-6.5%$1.08$1.08$1.01145,100
$1.08+0.03+2.9%$1.07$1.10$1.05159,003
$1.05-0.05-4.5%$1.10$1.10$1.0464,454
$1.10-0.02-1.8%$1.13$1.14$1.10143,800
$1.12-0.01-0.9%$1.13$1.14$1.07121,400

Splits

1 split · AMEX:ATNM · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
Ticker
NYSE American:ATNM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Actinium Pharmaceuticals, Inc. (Delaware) news

Actinium Pharmaceuticals, Inc. (Delaware) on 6ix

Sector
Health care
Industry
Biotechnology
News releases
28 in the last 12 months · 39 in all · newest Nov 17, 2026 · oldest 2025
Decks
24 decks · latest November 2026

Where Actinium Pharmaceuticals, Inc. (Delaware) is listed

ListingExchangeCountryCurrency
NYSE American:ATNM · Home listing · This pageNYSE AmericanUnited StatesUSD
Lang & Schwarz:A2QA48Lang & SchwarzGermanyEUR
gettex:7AY1gettexGermanyEUR
LS Exchange:A2QA48LS ExchangeGermanyEUR
Tradegate:7AY1TradegateGermanyEUR
BOATS:ATNMBOATSUnited StatesUSD
Stuttgart:7AY1StuttgartGermanyEUR
Dusseldorf:7AY1DusseldorfGermanyEUR
Frankfurt:7AY1FrankfurtGermanyEUR

Valuation

Price/book 1.3× against a median of 1.2×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.49M USD
P/E
3.1×
EV/sales
No revenue
EV/EBITDA
0.6×
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
0.71

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNMUS$33.01MUS$5.49M3.1×n/a0.6×1.3×n/a0.1×0.71
Cue Biopharma, Inc. · NASDAQ:CUEUS$34.69M−US$23.25Mn/a−0.7×n/a0.9×−580.0%0.0×2.35
B&K Corporation Limited Class H · HKEX:2396US$33.15M−US$47.10Mn/a−602×n/a0.4×n/a0.0×n/a
Veru Inc. · NASDAQ:VERUUS$33.08MUS$9.20Mn/an/an/a1.2×n/a0.0×1.92
Neurizon Therapeutics Limited · ASX:NUZUS$32.76MUS$26.54Mn/a2.3×n/a3.9×−61.0%0.3×n/a
CJ Bioscience. Inc. · KRX:311690US$32.52MUS$1.91Mn/a0.7×n/a1.0×−607.2%0.0×n/a
Transcenta Holding Limited · HKEX:6628US$32.41MUS$52.52Mn/a12.4×n/a0.4×−569.5%0.3×n/a
Enimmune Corporation · TPEX:6564US$31.74MUS$26.87Mn/a18.4×n/a10.4×−341.0%0.3×n/a
Molecure SA · GPW:MOCUS$31.66MUS$29.60Mn/an/an/a1.3×n/a0.0×n/a
Sareum Holdings plc · LSE:SARUS$31.03MUS$27.78Mn/an/an/a19.9×n/a0.0×n/a
Isofol Medical AB · OMXSTO:ISOFOLUS$31.03MUS$19.80Mn/an/an/a3.3×n/a0.0×n/a
Median of the othersUS$32.46MUS$23.17M1.5×1.2×−569.5%0.0×2.13

Forecasts

2 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Dec 2026
0.16 · 1 analyst
Revenue, year to Dec 2026
26.25M · 4 analysts

Team and board

Officers

OfficerRole
Sandesh SethChief Executive Officer and Chairman of the Board
Matt DavidChief Financial Officer
Paul DiamondVice President, Legal and Intellectual Property Counsel
Ryan ChuVice President, Finance and Investor Relations
Gary SiegelVice President, Controller
Julie GibsonVice President, Portfolio and Clinical Operations
Monideepa RoySenior Vice President, Corporate Development – R&D
Sean MaenpaaSenior Vice President, Business Development
Adeela KamalChief Scientific Officer
Steffen HeegerChief Medical Officer

Board

DirectorRole
Sandesh SethChief Executive Officer and Chairman of the Board
Ajit ShettyDirector
C. David NicholsonLead Independent Director
Jeffrey W. ChellDirector
June AlmenoffDirector
Richard l. SteinhartDirector

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−9.4%
Q2 2026Aug 7, 2026−2.2%
Q1 2026May 8, 2026 · After close+2.3%
Q4 2025Mar 13, 2026−1.8%
Q3 2025Nov 14, 2025 · After close+14.2%
Q2 2025Aug 8, 2025 · After close−4.5%
Q1 2025May 9, 2025 · After close+4.7%
Q4 2024Mar 27, 2025 · After close−4.2%
Q3 2024Nov 14, 2024 · After close−9.1%
Q2 2024Aug 5, 2024 · After close+15.7%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 26, 2024 · After close+7.4%
Q4 2023Mar 29, 2024 · After close+9.3%
Q3 2023Nov 2, 2023 · Before open−15.5%
Q2 2023Aug 14, 2023 · After close+2.4%
Q1 2023May 15, 2023 · After close−5.9%
Q4 2022Mar 31, 2023 · After close−2.6%
Q3 2022Nov 14, 2022 · After close−1.9%
Q2 2022Aug 12, 2022 · After close+1.9%
Q1 2022May 13, 2022 · After close−0.2%
Q4 2021Mar 25, 2022 · After close−3.0%

Open Events

Decks

DeckKindSlidesDate
Actinium Pharmaceuticals — Investor Presentation (November 2026)Investor deck36 slidesNovember 2026
Actinium Pharmaceuticals — Technical Presentation (October 2026)Technical12 slidesOct 19, 2026
Actinium Pharmaceuticals — Investor Presentation (October 2026)Investor deck26 slidesOctober 2026
Actinium Pharmaceuticals — 4th Annual Targeted Radiotherapeutics Summit 2025Conference24 slidesJul 30, 2025
Actinium Pharmaceuticals — Technical Presentation (March 2025)Technical43 slidesMar 25, 2025
Actinium Pharmaceuticals — Technical Presentation (May 2024)Technical35 slidesMay 20, 2024
Actinium Pharmaceuticals — Technical Presentation (February 2023)Technical30 slidesFeb 28, 2023
Actinium Pharmaceuticals — Investor Presentation (February 2023)Investor deck42 slidesFeb 21, 2023
Actinium Pharmaceuticals — Technical Presentation (February 2023)Technical42 slidesFeb 18, 2023
Actinium Pharmaceuticals — Technical Presentation (2023)Technical17 slides2023
All 24 decks
DeckKindSlidesDate
Actinium Pharmaceuticals — ASH 2023Conference11 slides2023
Actinium Pharmaceuticals — Technical Presentation (2022)Technical13 slides2022
Actinium Pharmaceuticals — Technical Presentation (2021)Technical11 slides2021
Actinium Pharmaceuticals — TCT Late Breaking Oral Presentation 2019Conference12 slides2019
Actinium Pharmaceuticals — Corporate Update (October 2018)Corporate update37 slidesOct 26, 2018
Actinium Pharmaceuticals — Corporate Update (September 2018)Corporate update35 slidesSep 26, 2018
Actinium Pharmaceuticals — American Society of Hematology (ASH) Annual Meeting 2018Conference12 slides2018
Actinium Pharmaceuticals — Technical Presentation (October 2014)Technical31 slidesOct 21, 2014
Actinium Pharmaceuticals — Investor Presentation (October 2014)Investor deck11 slidesOct 21, 2014
Actinium Pharmaceuticals — Investor Presentation (September 2014)Investor deck25 slidesSep 25, 2014
Actinium Pharmaceuticals — Investor Presentation (April 2014)Investor deck25 slidesApril 2014
Actinium Pharmaceuticals — Investor Presentation (April 2014)Investor deck26 slidesApril 2014
Actinium Pharmaceuticals — Biotech Showcase 2014Conference25 slidesJan 13, 2014
Actinium Pharmaceuticals — LD Micro Conference (December 2013)Conference21 slidesDec 9, 2013

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue90.0K081.0K1.03M1.14M622.0K0000
Cost of revenue811.0K790.0K699.0K900.0K447.0K420.1K50.7K55.9K77.5K
Gross profit90.0K-811.0K81.0K1.03M620.0K-447.0K-420.1K-50.7K-55.9K-77.5K
Research and development21.1M30.0M38.7M23.1M18.0M16.1M16.6M17.1M17.7M17.8M
Selling, general and administrative15.2M12.1M13.3M12.0M8.08M6.31M5.52M6.73M9.15M9.27M
Operating income-36.2M-42.1M-51.9M-34.1M-25.0M-22.4M-22.1M-23.8M-26.9M-26.8M
Depreciation and amortization173.0K197.0K207.0K699.0K524.0K447.0K420.0K50.7K55.9K77.5K
EBITDA-36.1M-41.9M-51.7M-33.4M-24.4M-21.9M-21.7M-23.8M-26.9M-26.8M
Interest expense1.09M190.0K00173.4K5.43K5.01K
Income before tax-33.3M-38.2M-48.8M-33.0M-24.8M-22.2M-21.9M-23.7M-26.6M-24.3M
Income tax622.1K-1.09M-190.0K-178.0K-172.0K173.4K-310.0K5.01K
Net income-33.9M-38.2M-48.8M-33.0M-24.8M-22.2M-21.9M-23.7M-26.6M-24.3M
Earnings per share, basic-1.09-1.27-1.83-1.37-1.20-1.83-4.40-0.22-0.40-0.50
Earnings per share, diluted-1.09-1.27-1.83-1.37-1.20-1.83-4.40-0.22-0.40-0.50

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents48.0M72.9M76.7M108.9M77.8M63.6M9.25M13.7M17.4M20.5M
Short-term investments35.0K
Current assets49.4M74.5M78.3M110.9M79.7M64.9M10.1M14.3M17.8M22.4M
Property, plant and equipment295.0K364.0K550.0K604.0K340.0K312.0K113.0K118.8K57.4K88.5K
Goodwill100.0K
Total assets51.8M76.9M81.4M114.2M80.4M66.4M11.7M14.9M18.3M22.5M
Accounts payable7.57M7.95M10.1M5.54M4.34M4.60M5.81M4.65M4.19M
Current liabilities7.97M8.15M8.49M10.6M6.84M4.77M5.34M6.06M4.67M4.52M
Long-term debt900.0K
Total debt1.69M1.57M2.11M2.58M310.0K738.0K1.43M262.6K
Total liabilities43.9M44.1M45.1M47.7M6.84M5.08M6.03M6.08M4.67M4.52M
Shareholders' equity7.83M32.8M36.4M66.5M73.5M61.3M5.64M8.81M13.7M18.0M
Shares outstanding31.2M31.2M27.6M25.7M22.1M17.5M5.49M115.7M80.1M55.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-24.6M-33.1M-47.3M8.64M-20.9M-21.6M-21.5M-20.6M-21.6M-20.8M
Capital spending-104.0K-11.0K-153.0K-366.0K-133.0K-253.0K-64.0K-96.1K-24.7K-60.0K
Free cash flow-24.7M-33.1M-47.5M8.28M-21.0M-21.9M-21.5M-20.7M-21.6M-20.8M
Cash from investing-104.0K-11.0K-153.0K-366.0K-133.0K-253.0K-64.0K-96.1K-24.7K-109.8K
Cash from financing-217.0K29.3M14.9M23.1M35.2M76.2M17.1M17.0M18.8M15.8M
Dividends paid-1.00K-1.27K
Share buybacks-207.0K35.3M1.00K1.27K17.0M18.8M16.0M
Change in cash-24.9M-3.76M-32.6M31.4M14.2M54.3M-4.41M-3.69M-2.76M-5.12M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
4 · Change in ownershipOct 16, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 16, 2026Insider tradeSEC
ARS · Annual report to shareholdersOct 16, 2026Annual reportSEC
DEF 14A · Proxy statementOct 16, 2026Meeting noticeSEC
8-K · Current reportOct 15, 2026Management or board changeSEC
S-8 · Registration statement for employee plansOct 9, 2026Offer documentSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
8-K · Current reportAug 14, 2026Current reportSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
8-K · Current reportJun 18, 2026Current reportSEC
8-K · Current reportMay 29, 2026Current reportSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K/A · Current report, amendedMar 26, 2026Meeting outcomeSEC
8-K · Current reportFeb 13, 2026Management or board changeSEC
8-K · Current reportNov 26, 2025Management or board changeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
ARS · Annual report to shareholdersNov 5, 2025Annual reportSEC
DEF 14A · Proxy statementNov 5, 2025Meeting noticeSEC
4 · Change in ownershipAug 20, 2025Insider tradeSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 9, 2025Current reportSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportNov 27, 2024Management or board changeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 8, 2024Big-stake noticeSEC
ARS · Annual report to shareholdersNov 6, 2024Annual reportSEC
4 · Change in ownershipNov 5, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 5, 2024Insider tradeSEC
8-K · Current reportNov 5, 2024Management or board changeSEC
DEF 14A · Proxy statementNov 5, 2024Meeting noticeSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2024Quarterly reportSEC
8-K · Current reportAug 5, 2024Current reportSEC
10-Q · Quarterly reportApr 26, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansMar 29, 2024Offer documentSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 6, 2024Other filingsSEC
S-3/A · Registration statement, amendedFeb 2, 2024Offer documentSEC
CORRESP · Letter to the SECFeb 2, 2024Other filingsSEC
SC 13G · Big-stake noticeJan 29, 2024Big-stake noticeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
8-K · Current reportDec 1, 2023Management or board changeSEC
ARS · Annual report to shareholdersNov 9, 2023Annual reportSEC
DEF 14A · Proxy statementNov 9, 2023Meeting noticeSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
UPLOAD · Letter from the SECAug 17, 2023Other filingsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
S-3 · Registration statementAug 11, 2023Offer documentSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 10, 2023Current reportSEC
8-K · Current reportFeb 21, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2023Big-stake noticeSEC
8-K · Current reportDec 30, 2022Management or board changeSEC
DEFA14A · Additional proxy materialDec 9, 2022Meeting noticeSEC
8-K · Current reportDec 9, 2022Current reportSEC
DEF 14A · Proxy statementNov 21, 2022Meeting noticeSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportOct 31, 2022Current reportSEC
S-8 · Registration statement for employee plansAug 19, 2022Offer documentSEC
4 · Change in ownershipAug 19, 2022Insider tradeSEC
10-Q · Quarterly reportAug 12, 2022Quarterly reportSEC
4 · Change in ownershipJul 1, 2022Insider tradeSEC
4 · Change in ownershipJul 1, 2022Insider tradeSEC
4 · Change in ownershipJul 1, 2022Insider tradeSEC
4 · Change in ownershipJul 1, 2022Insider tradeSEC
4 · Change in ownershipJul 1, 2022Insider tradeSEC
4 · Change in ownershipJul 1, 2022Insider tradeSEC
8-K · Current reportJun 29, 2022Material contractSEC
424B3 · ProspectusJun 28, 2022Offer documentSEC
10-Q · Quarterly reportMay 13, 2022Quarterly reportSEC
8-K · Current reportApr 13, 2022Material contractSEC
10-K · Annual reportMar 25, 2022Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2022Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2021Quarterly reportSEC
8-K · Current reportNov 9, 2021Management or board changeSEC
DEFA14A · Additional proxy materialNov 4, 2021Meeting noticeSEC
DEF 14A · Proxy statementOct 18, 2021Meeting noticeSEC
8-K · Current reportSep 23, 2021Management or board changeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
4 · Change in ownershipSep 3, 2021Insider tradeSEC
10-Q · Quarterly reportJul 30, 2021Quarterly reportSEC
10-Q · Quarterly reportMay 14, 2021Quarterly reportSEC
10-K · Annual reportMar 31, 2021Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2021Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 5, 2021Big-stake noticeSEC
8-K · Current reportNov 20, 2020Management or board changeSEC
DEFA14A · Additional proxy materialOct 28, 2020Meeting noticeSEC
8-K · Current reportOct 28, 2020Current reportSEC
10-Q · Quarterly reportOct 23, 2020Quarterly reportSEC
DEFA14A · Additional proxy materialOct 7, 2020Meeting noticeSEC
DEF 14A · Proxy statementOct 7, 2020Meeting noticeSEC
EFFECT · Notice that a registration is effectiveAug 17, 2020Other filingsSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
10-Q · Quarterly reportAug 14, 2020Quarterly reportSEC
8-K · Current reportAug 14, 2020Current reportSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
4 · Change in ownershipAug 14, 2020Insider tradeSEC
CORRESP · Letter to the SECAug 14, 2020Other filingsSEC
UPLOAD · Letter from the SECAug 13, 2020Other filingsSEC
SC 13G · Big-stake noticeAug 11, 2020Big-stake noticeSEC
S-3 · Registration statementAug 7, 2020Offer documentSEC
8-K · Current reportAug 5, 2020Current reportSEC
8-K · Current reportJul 24, 2020Current reportSEC
10-K/A · Annual report, amendedJul 13, 2020Annual reportSEC
10-Q · Quarterly reportJun 29, 2020Quarterly reportSEC
8-K · Current reportJun 19, 2020Current reportSEC
8-K · Current reportJun 18, 2020Material contractSEC
424B5 · ProspectusJun 18, 2020Offer documentSEC
8-K · Current reportJun 16, 2020Current reportSEC
424B5 · ProspectusJun 16, 2020Offer documentSEC
8-K · Current reportJun 16, 2020Current reportSEC
10-K/A · Annual report, amendedJun 16, 2020Annual reportSEC
8-K · Current reportMay 15, 2020Current reportSEC
10-K · Annual reportMay 8, 2020Annual reportSEC
8-K · Current reportMay 5, 2020Current reportSEC
8-K · Current reportMay 5, 2020Current reportSEC
SC 13G · Big-stake noticeMay 1, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedApr 27, 2020Big-stake noticeSEC
8-K · Current reportApr 24, 2020Material contractSEC
424B5 · ProspectusApr 22, 2020Offer documentSEC
424B5 · ProspectusApr 21, 2020Offer documentSEC
8-K · Current reportMar 27, 2020Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2020Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 7, 2020Big-stake noticeSEC
8-K · Current reportDec 19, 2019Meeting outcomeSEC
8-K · Current reportDec 3, 2019Current reportSEC
DEF 14A · Proxy statementNov 25, 2019Meeting noticeSEC
8-K · Current reportNov 25, 2019Management or board changeSEC
PRE 14A · Preliminary proxy statementNov 15, 2019Meeting noticeSEC
10-Q · Quarterly reportNov 12, 2019Quarterly reportSEC
SC 13G · Big-stake noticeOct 30, 2019Big-stake noticeSEC
10-Q · Quarterly reportAug 9, 2019Quarterly reportSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
4 · Change in ownershipJul 16, 2019Insider tradeSEC
8-K · Current reportJun 7, 2019Current reportSEC
10-Q · Quarterly reportMay 10, 2019Quarterly reportSEC
S-8 · Registration statement for employee plansMay 10, 2019Offer documentSEC
8-K · Current reportApr 18, 2019Material contractSEC
424B5 · ProspectusApr 18, 2019Offer documentSEC
SC 13G · Big-stake noticeApr 18, 2019Big-stake noticeSEC
424B5 · ProspectusApr 17, 2019Offer documentSEC
10-K · Annual reportMar 15, 2019Annual reportSEC
8-K · Current reportMar 12, 2019Material contractSEC
4 · Change in ownershipMar 7, 2019Insider tradeSEC
4 · Change in ownershipFeb 21, 2019Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2019Big-stake noticeSEC
424B5 · ProspectusDec 28, 2018Offer documentSEC
8-K · Current reportDec 28, 2018Material contractSEC
8-K · Current reportDec 26, 2018Management or board changeSEC
8-K · Current reportDec 21, 2018Meeting outcomeSEC
4 · Change in ownershipDec 10, 2018Insider tradeSEC
4 · Change in ownershipDec 10, 2018Insider tradeSEC
4 · Change in ownershipNov 20, 2018Insider tradeSEC
DEF 14A · Proxy statementNov 16, 2018Meeting noticeSEC
10-Q · Quarterly reportNov 9, 2018Quarterly reportSEC

This page holds 200 of 512 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Actinium Pharmaceuticals, Inc. (Delaware)’s releases · as of Nov 13, 2026

Common shares
31,441,436
Fully diluted
31,441,436

Fully diluted

LineSharesAs of
Common shares31,441,436Nov 13, 2026

Share count over time

CountShares
Nov 13, 202631,441,436

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard1.44M4.6%US$1.62MSep 30, 2026
Millennium484K1.5%US$542KSep 30, 2026
Acadian Asset Management LLC481K1.5%US$537KSep 30, 2026
BlackRock391K1.2%US$438KSep 30, 2026
Compass Financial Management LLC389K1.2%US$436KSep 30, 2026
Renaissance Technologies343K1.1%US$384KSep 30, 2026
Geode Capital325K1.0%US$364KSep 30, 2026
Two Sigma235K0.75%US$263KSep 30, 2026
Gagnon Securities LLC182K0.58%US$204KSep 30, 2026
State Street122K0.39%US$137KSep 30, 2026
All 48 holders
HolderSharesOf the companyValueAs of
Am Investment Strategies LLC92,8560.30%US$104KSep 30, 2026
Northern Trust69,7430.22%US$78,112Sep 30, 2026
Gen-Wealth Partners Inc59,8260.19%US$67,005Sep 30, 2026
Bluespring Wealth Management, LLC50,0000.16%US$56,000Sep 30, 2026
Vontobel Holding Ltd.50,0000.16%US$56,000Sep 30, 2026
Keel Point, LLC41,0940.13%US$46,025Sep 30, 2026
Bridgeway Capital Management, LLC39,3540.13%US$44,076Sep 30, 2026
Empowered Funds, LLC39,3540.13%US$44,076Sep 30, 2026
Susquehanna31,7330.10%US$35,541Sep 30, 2026
Mayport, LLC22,0000.07%US$24,640Sep 30, 2026
Gerald Baker Financial Group LLC19,9200.06%US$22,310Sep 30, 2026
Osaic Holdings, Inc.18,7400.06%US$20,988Sep 30, 2026
Hrt Financial LP16,5530.05%US$18,000Sep 30, 2026
Wells Fargo15,0000.05%US$16,800Sep 30, 2026
Citadel13,9210.04%US$15,592Sep 30, 2026
Prudential Financial Inc13,4000.04%US$15,008Sep 30, 2026
Qube Research & Technologies Ltd12,1820.04%US$13,644Sep 30, 2026
Savvy Advisors, Inc.10,0000.03%US$11,200Sep 30, 2026
Citigroup Inc8,7890.03%US$9,844Sep 30, 2026
Rockefeller Capital Management L.P.4,0000.01%US$4,480Sep 30, 2026
Morgan Stanley2,466<0.01%US$2,762Sep 30, 2026
Steward Partners Investment Advisory, LLC2,000<0.01%US$2,240Sep 30, 2026
JPMorgan1,494<0.01%US$1,703Sep 30, 2026
Jones Financial Companies Lllp1,351<0.01%US$1,621Sep 30, 2026
Fidelity1,333<0.01%US$1,493Sep 30, 2026
National Bank Of Canada921<0.01%US$1,032Sep 30, 2026
SBI Securities Co., Ltd.492<0.01%US$551Sep 30, 2026
Pittenger & Anderson Inc341<0.01%US$382Sep 30, 2026
Tower Research Capital LLC (TRC)336<0.01%US$376Sep 30, 2026
Harbour Investments, Inc.334<0.01%US$374Sep 30, 2026
Investors Research Corp300<0.01%US$336Sep 30, 2026
BNP Paribas201<0.01%US$225Sep 30, 2026
Northwestern Mutual Wealth Management Co107<0.01%US$120Sep 30, 2026
UBS55<0.01%US$62Sep 30, 2026
RBC47<0.01%Sep 30, 2026
Barclays31<0.01%US$34Sep 30, 2026
Cassaday & Co Wealth Management LLC16<0.01%US$18Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund919K2.9%US$900KJun 30, 2026
Vanguard Extended Market Index Fund315K1.0%US$309KJun 30, 2026
Fidelity Extended Market Index Fund171K0.55%US$216KMay 31, 2026
iShares Micro-Cap ETF107K0.34%US$105KJun 30, 2026
Fidelity Total Market Index Fund52,2870.17%US$65,882May 31, 2026
Fidelity Series Total Market Index Fund44,5300.14%US$56,108May 31, 2026
Ultra-Small Company Market Fund40,0000.13%US$39,200Jun 30, 2026
1290 VT Micro Cap Portfolio5,8490.02%US$5,732Jun 30, 2026
Vanguard Balanced Index Fund4,3760.01%US$4,288Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund3,114<0.01%US$3,052Jun 30, 2026
All 11 holders
HolderSharesOf the companyValueAs of
Knights of Columbus U.S. ALL CAP INDEX FUND175<0.01%US$146Jul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rosemary Mazanet
Other companies: Kairos Pharma, Ltd. (Director · Sep 16, 2024 – Sep 16, 2024 · Past); SELLAS Life Sciences Group, Inc. (Chief Medical Officer · Feb 1, 2012 – Jan 29, 2013 · Past); Abeona Therapeutics Inc. (Director · Jan 4, 2007 – Jan 4, 2007 · Past); Aksys Ltd (Director · Aug 9, 2006 – Oct 24, 2006 · Past); Oncternal Therapeutics Inc (Director · Jan 1, 2006 – Jun 20, 2024 · Past)
Director · Dec 28, 2012 – May 15, 2013 · Past
Richard I. Steinhart
Other companies: BioXcel Therapeutics, Inc. (Senior Vice President and Chief Financial Officer · Since at least Mar 7, 2018); Atossa Therapeutics, Inc. (Director · Since at least Mar 1, 2014); MELA Sciences Inc (Chief Financial Officer · May 14, 2010 – Aug 5, 2013 · Past); TG Therapeutics, Inc. (Director · Mar 25, 2008 – Mar 3, 2010 · Past)
Director · Since at least Nov 8, 2013
Anil Kapur
Other companies: Nurix Therapeutics, Inc. (Director · Since at least Oct 15, 2024); Verastem, Inc. (Member, Audit Committee; Member, Compensation Committee; Member, Commercialization Committee · Since at least Oct 20, 2022); Geron Corporation (EVP, Corp Strategy & CCO · Dec 2, 2019 – Jun 10, 2024 · Past)
Chief Commercial Officer · Feb 6, 2018 – Jul 12, 2019 · Past
June Almenoff
Other companies: Tenax Therapeutics, Inc. (Director · Since at least Dec 10, 2024); Avalo Therapeutics, Inc. (Director · Since at least Dec 20, 2023)
Director · Since at least Nov 1, 2024
C. David Nicholson
Other companies: Adverum Biotechnologies Inc (Director · Since at least Nov 3, 2023)
Director · Since at least Dec 28, 2023
Dragan Cicic
Other companies: SELLAS Life Sciences Group, Inc. (Senior Vice President, Chief Development Officer · Since at least Jun 20, 2024)
Chief Technology Officer · Dec 28, 2012 – Mar 14, 2017 · Past
Kaushik J Dave
Other companies: Antares Pharma Inc (Executive Vice President · May 6, 2013 – Jun 3, 2013 · Past)
CEO and Interim CFO, Director · Sep 16, 2013 – Mar 14, 2017 · Past
Mark Stanley Berger
Other companies: Genprex, Inc. (Chief Medical Officer · Since at least Sep 27, 2021)
Chief Medical Officer · Mar 16, 2017 – Sep 1, 2021 · Past
Steve O'Loughlin
Other companies: CNS Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Mar 2, 2026)
Chief Financial Officer · Sep 1, 2021 – Mar 31, 2025 · Past
Adeela KamalChief Scientific Officer · Since at least Sep 3, 2026
All 24 people
PersonSeat
Ajit ShettyDirector · Since at least Mar 28, 2017
Enza GuagentiChief Financial Officer · Dec 28, 2012 – Dec 28, 2012 · Past
Gary SiegelVice President, Controller · Since at least Nov 5, 2026
Jeffrey W. ChellDirector · Since at least Apr 27, 2018
Julie GibsonVice President, Portfolio and Clinical Operations · Since at least Nov 5, 2026
Matt DavidChief Financial Officer · Since at least Oct 15, 2026
Matthew T DavidChief Financial Officer · Since at least Oct 14, 2026
Monideepa RoySenior Vice President, Corporate Development – R&D · Since at least Apr 22, 2026
Paul DiamondVice President, Legal and Intellectual Property Counsel · Since at least Nov 5, 2026
Richard l. SteinhartDirector · Since at least Sep 4, 2026
Ryan ChuVice President, Finance and Investor Relations · Since at least Nov 5, 2026
Sandesh SethChief Executive Officer and Chairman of the Board · Since at least Mar 31, 2025
Sean MaenpaaSenior Vice President, Business Development · Since Oct 12, 2026
Steffen HeegerChief Medical Officer · Since at least Jun 1, 2026

Open People

Log in to ask 6ix AI your own questions about Actinium Pharmaceuticals, Inc. (Delaware).